Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data
Open Access
- 15 April 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (Supplement), S164-S172
- https://doi.org/10.1086/500663
Abstract
Nosocomial infections caused by extended-spectrum β-lactamase (ESBL)—producing gram-negative bacteria complicate therapy and limit treatment options. However, the clinical significance of infections caused by ESBL-producing bacteria remains unclear. A critical examination of the literature provides divergent views of the effect of ESBL carriage on morbidity and mortality and suggests that ESBL production may have its most marked effect on ceftazidime. Effective strategies for the empirical and directed treatment of infections caused by ESBL-producing pathogens include the use of carbapenems and, possibly, the fourth-generation cephalosporin cefepime. Studies indicate that the use of cefepime to treat serious nosocomial infections (e.g., bacteremia, pneumonia, and urinary tract infections) is associated with high rates of microbiological and clinical success. The probability of attaining time above the minimum inhibitory concentration targets of at least 70% of the dosing interval, an important pharmacodynamic indicator of clinical success, is higher with cefepime than with other antimicrobials against Escherichia coli and Klebsiella pneumoniae strains exhibiting ESBL phenotypes. However, for non–ESBL-producing strains, there is no difference in the time above the minimum inhibitory concentration between ceftazidime and cefepime. When used appropriately in institutional settings, cefepime reduces the overall use of cephalosporins, thereby decreasing selection pressure for presumptive ESBL-producing pathogens.Keywords
This publication has 46 references indexed in Scilit:
- The inoculum effect: Fact or artifact?Diagnostic Microbiology and Infectious Disease, 2004
- Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST ProgramAntimicrobial Agents and Chemotherapy, 2003
- Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997–2000)International Journal of Antimicrobial Agents, 2003
- Molecular Epidemiology of Extended-Spectrum β-Lactamase-Producing, Fluoroquinolone-Resistant Isolates of Klebsiella pneumoniae in TaiwanJournal of Clinical Microbiology, 2002
- TEM-71, a Novel Plasmid-Encoded, Extended-Spectrum β-Lactamase Produced by a Clinical Isolate of Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2002
- Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99)Diagnostic Microbiology and Infectious Disease, 2002
- Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused byEscherichia coliandKlebsiella pneumoniaewith Reduced Susceptibility to CeftazidimeClinical Infectious Diseases, 2002
- Piperacillin/Tazobactam in the Treatment ofKlebsiella PneumoniaeInfections in NeonatesAmerican Journal of Perinatology, 1998
- Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Bloodstream Infection: A Case-Control and Molecular Epidemiologic InvestigationThe Journal of Infectious Diseases, 1996
- TRANSFERABLE ENZYMATIC RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS DURING NOSOCOMIAL OUTBREAK OF MULTIRESISTANT KLEBSIELLA PNEUMONIAEThe Lancet, 1987